Clinical Trial

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Name: A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH — clinical trial record (NCT07221227)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ZENITH-1

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.

Trial Details

NCT Number	NCT07221227
Lead Sponsor	GlaxoSmithKline
Conditions	Non-alcoholic Fatty Liver Disease
Enrollment	1,200 participants
Start Date	2025-10-24
Primary Completion	2028-03-29 (estimated)
Study Completion	2031-12-12 (estimated)
Updated on ClinicalTrials.gov	2026-04-16